Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations

European Journal of Neurology

Volumn 22, Issue , 2015, Pages 14-21

  Gallo, P ^a   Van Wijmeersch, B ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Disease modifying therapy; Escalation; Glatiramer acetate; Interferon beta; Multiple sclerosis, propensity score; Relapsing remitting; Switching

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; TERIFLUNOMIDE; IMMUNOLOGIC FACTOR;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; IMMUNOMODULATION; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROPENSITY SCORE; TREATMENT INDICATION; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT; PROCEDURES;

HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84941631986     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12799     Document Type: Article

References (22)

1. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987-997.
2. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511.
3. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
4. Miller A, Wolinsky J, Kappos L, et al. Efficacy and safety of once-daily oral teriflunomide in patients with first clinical episode consistent with multiple sclerosis. Neurol 2014; 82 (10 Suppl): PL2.002.
5. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089-1104.
6. Leocani L, Rovaris M, Boneschi FM, et al. Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. J Neurol Neurosurg Psychiatry 2006; 77: 1030-1035.
7. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010; 9: 921-932.
8. Sormani MP, Rio J, Tintorè M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013; 19: 605-612.
9. Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 2013; 12: 669-676.
10. Río J, Tintoré M, Sastre-Garriga J, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol 2012; 19: 899-904.
11. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006; 13: 471-474.
12. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 50-58.
13. Carrá A, Onaha P, Luetic G, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008; 15: 386-393.
14. Prosperini L, Borriello G, De Giglio L, Leonardi L, Barletta V, Pozzilli C. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of interferon beta dose should be effective? BMC Neurol 2011; 11: 26.
15. Prosperini L, Giannì C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 2012; 18: 64-71.
16. Belachew S, Phan-Ba R, Bartholomé E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2011; 18: 240-245.
17. Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V. Natalizumab is effective as second line therapy in the treatment of relapsing-remitting multiple sclerosis. Eur J Neurol 2009; 16: 424-426.
18. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009; 16: 420-423.
19. Spelman T, Kalincik T, Pellegrini F, et al. Comparison of switching to natalizumab versus remaining on interferon-beta or glatiramer acetate after on-treatment MS relapse using propensity-matched registry data [Poster]. Neurol 2014; 82 (10 Suppl): P7.208.
20. Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85: 1190-1197.
21. Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One 2014; 9: e88472.
22. Clerico M, Schiavetti I, De Mercanti SF, et al. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol 2014; 71: 954-960.